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The presence of liver metastases, before or 
after removal of primary lesions, compro-
mises the long-term survival of colorectal 
cancer patients. Therefore, effective treat-
ments against this disease should avoid 
liver colonization and dissemination of 
cancer cells in this organ. A clinical set-
ting presenting diffuse deposits but rela-
tively low tumor burden is, in principle, 
a favorable scenario for immunotherapy. 
However, tumors thrive in an environ-
ment hostile for the establishment of 
efficient immune responses, in part due 
to the accumulation of T regulatory cells 
(Tregs) and myeloid-derived suppressor 
cells (MDSC).1
The ability of certain chemothera-
peutic agents to stimulate the immune 
system is emerging as a key determinant 
of their antitumor properties.2 Among 
them, oxaliplatin (OXP) has been recently 
described to increase the immunogenic-
ity of cancer cells.3 However, standard 
chemotherapy protocols designed to max-
imize the cytotoxic effect have shown lim-
ited efficacy against metastatic colorectal 
cancer. Hopefully, strategies that favor the 
immunostimulatory properties of these 
drugs might change this situation. In a 
recent report in reference 4, we describe 
that OXP used in combination with 
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interleukin-12 (IL-12) is able to eradicate 
pre-existing liver metastases of colorectal 
cancer and to protect from relapse in a 
murine model.
IL-12 is a potent immunostimula-
tory cytokine that activates the prolif-
eration and function of key mediators of 
the innate and adaptive systems such as 
T lymphocytes and natural killer (NK) 
cells. The ability of IL-12 to stimulate 
the immune response against tumors has 
been extensively demonstrated.5 The sys-
temic toxicity of this cytokine is a seri-
ous obstacle for its use as a recombinant 
protein in humans, but genetic transfer 
to specific locations is an attractive alter-
native. Adenoviral vectors carry out effi-
cient gene transfer to the liver in humans. 
However, transgene expression with early 
versions is transient, and the efficacy of re-
administration is severely impaired by the 
rapid appearance of neutralizing antibod-
ies. The use of high-capacity (also called 
helper-dependent or “gutless”) adenovi-
ral vectors (HC-Ads) allows long-term 
expression in animal models after a single 
administration, and their extended clon-
ing capacity facilitates the incorporation of 
inducible expression systems.6 These fea-
tures have been introduced in the HC-Ad/
RUmIL-12 vector designed to fight against 
primary or metastatic liver cancer.7 It con-
tains a liver-specific, mifepristone-induc-
ible system for the expression of murine 
IL-12 that allows a tight control on the 
intensity and duration of cytokine expres-
sion. Following vector administration, the 
induction regime is adjusted based on the 
response to a low dose of mifepristone, to 
compensate for differences in viral trans-
duction. In addition, a step-wise increase 
of inducer is needed to cope with the tran-
sient silencing of liver-specific promoters 
caused by gamma-interferon.8 We found 
that this individualized protocol allowed 
several cycles of IL-12 expression in the 
therapeutic range.4,7 Using a syngeneic 
model of liver metastases in mice, we 
observed that a single cycle consisting on 
10 daily inductions significantly extended 
the survival of animals and achieved erad-
ication of hepatic tumors in 50% of them 
(Fig. 1B). Importantly, a single dose of 
OXP administered 3 d before the initia-
tion of IL-12 induction increased the rate 
of tumor eradication above 80%, whereas 
the same dose of drug had no significant 
antitumor effect by its own. In principle, 
this improvement in the therapeutic effect 
is not surprising, because it may reflect 
collaboration with the cytotoxic effect on 
cancer cells. In fact, the same phenomenon 
Using a murine model of liver metastases, we found that oxaliplatin can enhance the immunostimulatory effect 
of interleukin-12 delivered by an adenoviral vector. A shift toward a favorable immune microenvironment was observed 
in tumors, with a relative increase in CD8+ T cells vs. T regulatory and myeloid-derived suppressor cells.
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When we studied the potential mecha-
nisms behind this fact, we found that 
OXP was the only drug that promoted a 
favorable immune microenvironment in 
the tumors (Fig. 1D and E). In accor-
dance with previous reports, 5-FU and 
had something special, because animals 
cured from their hepatic tumors showed 
an improved immunological protection 
from a subcutaneous tumor rechallenge 
(Fig. 1C), whereas this did not occur when 
IL-12 was combined with Iri or Gem. 
occurred when IL-12 was combined with 
other chemotherapeutics frequently used 
in the treatment of colorectal cancer, such 
as irinotecan (Iri) and gemcitabine (Gem), 
but not 5-Fluorouracil (5-FU) (Fig. 1B). 
However, we found that the effect of OXP 
Figure 1. IL-12 and oxaliplatin cooperate to induce an efficient immune response against tumors. Schematic representation of experiments, includ-
ing schedule and description of treatment groups (A). Hepatic tumors were established by intrahepatic inoculation of murine colon cancer cells in 
syngeneic C57BL/6 mice. The HC-Ad/RUmIL-12 vector was administered by direct hepatic injection in the liver surrounding the tumors, and expression 
of IL-12 was activated by daily injections of mifepristone (Mif). Some mice were treated with intraperitoneal chemotherapy using single agents (OXP, 
5-FU, Iri or Gem, named collectively CTH). Other groups received the same drugs preceding IL-12 expression (CTH+IL12). The presence of tumors was 
evaluated by direct inspection through laparotomy one month after initiation of treatments. (B) Percentage of tumor-free animals. No tumor regres-
sions were observed in control animals or those treated with chemotherapy alone, and are not represented in the graphic. (C) Cured animals received 
a subcutaneous inoculation of the same cancer cells, and the graphic shows the proportion of mice that were completely protected (absence of tumor 
growth). (D and E) In a separate set of experiments, tumor samples were obtained in the course of the treatments. Leucocytes were isolated and CD8+ 
T cells, Tregs (CD25+ FoxP3+) and monocytic MDSC (CD11b+ Ly6C+ Ly6G-) were identified by flow cytometry. The fold increase in the ratio of CD8/Treg 
and CD8/MDSC for each group is represented in (D and E), respectively, considering the control group as a reference. *p < 0.05; p < 0.005 (analysis of 
variance).
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activation of IL-12 expression can be 
scheduled as needed according to the evo-
lution of the patient. We believe this opens 
new possibilities in the field of immuno-
chemotherapy. Nevertheless, the function 
of all the components integrating the vec-
tor system should be carefully evaluated 
in pilot clinical trials before we can safely 
proceed to the implementation of this 
strategy in cancer patients.
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